abstract |
A novel peptide is provided. The present invention provides modified vasoactive intestinal peptide (VIP), encoding polynucleotides and vectors, and pharmaceutical compositions comprising the same. The present invention further provides methods for producing and using modified VIP agents. According to the present invention, VIP exhibits altered circulation binding half-life, receptor binding, or biological effectiveness, and / or altered receptor binding profile relative to unmodified VIP. [Selection] Figure 1 |